Healthcare / BiotechnologyNasdaqGM
$8.19
-0.26 (-3.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-38.7M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$643M
P/E
3.8x
↓EV/EBITDA
4.0x
↓ROE
40.2%
↑Gross Margin
88.5%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
55.4%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $311.7M · net income $163.1M · FCF $172.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $311.7M | $311.7M | $43.5M | — | $65408.00 | $190936.00 | $239231.00 | $283266.00 | $429797.00 | $329327.00 | $224105.00 | $210130.00 | $189274.00 | $2001.00 | $0.00 | — | — | — | — | — |
| Net Income | $163.1M | $163.1M | $-17.9M | $-46.3M | $-29.7M | $-28.2M | $-22.0M | $-16.4M | $-26.8M | $-33.0M | $-24.6M | $-18.2M | $-20.5M | $-9.1M | $-3.4M | $-6.7M | $-10.9M | $-8.1M | $-9.0M | $-7.2M |
| EBITDA | $167.3M | $167.3M | $-19.0M | $-46.2M | $-30.2M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 2.04 | 2.04 | -0.30 | -0.91 | -0.74 | -0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 88.5% | 88.5% | 92.7% | — | 94.3% | 22.0% | 14.4% | -31.8% | 7.7% | 65.1% | -63.6% | -51.7% | -135.5% | -9975.2% | — | — | — | — | — | — |
| Operating Margin | 48.2% | 48.2% | -51.4% | — | -46819.9% | -15417.5% | -11378.4% | -7416.3% | -6250.4% | -9997.4% | -11048.8% | -7925.6% | -4703.3% | -245646.9% | — | — | — | — | — | — |
| Net Margin | 52.3% | 52.3% | -41.2% | — | -45409.9% | -14774.7% | -9207.7% | -5801.3% | -6242.4% | -10023.4% | -10996.5% | -8655.4% | -10806.3% | -456426.7% | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.37 | 0.37 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.98 | 2.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $172.8M | $172.8M | $-50.7M | $-38.7M | $-24.6M | $-22.6M | $-22.1M | $-15.1M | $-23.7M | $-28.7M | $-22.3M | $-12.5M | $-6.3M | $-3.7M | $-2.3M | $-6.3M | $-3.7M | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | 40.2% | 40.2% | -21.2% | -66.1% | -53.9% | -44.9% | -49.8% | -69.5% | -543.7% | -458.9% | -138.3% | -53.5% | -562.8% | 227.1% | 1008.0% | -501.0% | -150.3% | 55.2% | 74.8% | 164.6% |
| Valuation | ||||||||||||||||||||
| P/E | 3.77 | 3.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 3.95 | 3.95 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.62 | 1.62 | 5.69 | 2.46 | 3.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 617.0% | 617.0% | — | — | — | -20.2% | -15.5% | -34.1% | 30.5% | 47.0% | 6.7% | 11.0% | 9359.0% | — | — | — | — | — | — | — |
| EPS Growth | 780.0% | 780.0% | 67.0% | -23.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-29.1%
EPS terminal req.
$0.73
Spread vs growth
809.1%
5Y implied EPS CAGR
-15.5%
EPS terminal req.
$0.88
Spread vs growth
795.5%
10Y implied EPS CAGR
-3.6%
EPS terminal req.
$1.42
Spread vs growth
783.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.30 → 2.04
Residual
-35.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.